Terraflora Daily Care and Gastrointestinal Health

A Randomized, Placebo-Controlled Trial Evaluating the Impact of a Synbiotic Dietary Supplement on Markers of Gastrointestinal Health

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07355634

Enrollment

Registered

2026-01-21

Start date

2026-01-12

Completion date

2026-09-01

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal

Brief summary

A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.

Interventions

DIETARY_SUPPLEMENTSynbiotic Dietary Supplement

12 weeks of supplementation with Enviromedica - Terraflora Daily Care

DIETARY_SUPPLEMENTPlacebo

Placebo capsule

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adult males or females age ≥ 25 years 2. Ability to read and speak English 3. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)

Exclusion criteria

1. Daily use within the past month of any probiotic or prebiotic supplement 2. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis 3. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications 4. Current daily tobacco smoker 5. Known allergies to any substance in the study products 6. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks 7. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol 8. Current participation in another clinical trial 9. Participants unable to provide consent

Design outcomes

Primary

Measure	Time frame
GA-Map Dysbiosis on GI360 Profile	4 weeks, 12 weeks

Secondary

Measure	Time frame	Description
Percentage of participants with dysfunction on GI360 Profile	4 weeks, 12 weeks	—
Gastrointestinal Symptom Rating Scale	4 weeks, 12 weeks	Minimum value: 1, Maximum value: 7, Higher scores represent more severe/troublesome symptoms.

Countries

United States

Contacts

CONTACTChris D'Adamo, Ph.D.

chris@ovationlab.com240-232-2103

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 12, 2026